We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

45 hedge funds and large institutions have $1.69M invested in Oncolytics Biotech in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

22% more funds holding

Funds holding: 37 → 45 (+8)

0.28% more ownership

Funds ownership: 1.91% → 2.2% (+0.28%)

39% less capital invested

Capital invested by funds: $2.79M → $1.69M (-$1.1M)

Holders
45
Holders Change
+8
Holders Change %
+21.62%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
11
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ARC
Advisor Resource Council
Texas
+$185K
2
Citadel Advisors
Citadel Advisors
Florida
+$145K
3
TSS
Two Sigma Securities
New York
+$50.1K
4
Renaissance Technologies
Renaissance Technologies
New York
+$47.3K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$36.9K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$206K
2
UBS Group
UBS Group
Switzerland
-$43.4K
3
Bank of America
Bank of America
North Carolina
-$22.5K
4
CCM
Chiron Capital Management
Florida
-$21K
5
CGA
Crescent Grove Advisors
Illinois
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
ZB
26
Zions Bancorporation
Utah
$7K – – –
Toronto Dominion Bank
27
Toronto Dominion Bank
Ontario, Canada
$7K +$7.11K +3,848 +295%
TCOV
28
Trust Company of Vermont
Vermont
$7K +$9.24K +5,000 New
National Bank of Canada
29
National Bank of Canada
Quebec, Canada
$6K +$8.33K +4,508 New
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.71K – – –
UBS Group
31
UBS Group
Switzerland
$4K -$43.4K -23,485 -88%
Osaic Holdings
32
Osaic Holdings
Arizona
$4K – – –
ACM
33
Aquatic Capital Management
Illinois
$4K +$4.81K +2,600 New
Wells Fargo
34
Wells Fargo
California
$3K +$555 +300 +19%
TRCT
35
Tower Research Capital (TRC)
New York
$3K +$3.17K +1,714 New
TWC
36
TD Waterhouse Canada
Ontario, Canada
$2.62K +$2.75K +1,489 New
Fifth Third Bancorp
37
Fifth Third Bancorp
Ohio
$1K – – –
SN
38
Sittner & Nelson
Oregon
$1K – – –
CCM
39
Chiron Capital Management
Florida
– -$21K -10,200 Closed
CGA
40
Crescent Grove Advisors
Illinois
– -$21K -10,000 Closed
IA
41
IFP Advisors
Florida
– -$10K -5,000 Closed
HI
42
Harbour Investments
Wisconsin
– -$5K -2,330 Closed
CAPTRUST Financial Advisors
43
CAPTRUST Financial Advisors
North Carolina
– +$2 +1 New
RPCONE
44
Retirement Planning Company of New England
Rhode Island
– +$78 +42 New
SPIA
45
Steward Partners Investment Advisory
New York
– +$185 +100 New
1
2

ONCY Hedge Fund Activity: Q4 2021 in Review

45 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2021, worth a combined $1.69M — down 39% from $2.79M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ONCY positions and 4 closed out — a net gain of 8 holders — while 11 added to existing stakes and 4 trimmed.

The largest buyer was Advisor Resource Council, opening a new position worth an estimated $185K. The largest seller was JP Morgan Chase, cutting an estimated $206K.

  • 45 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2021, up from 37 in Q3 2021.
  • Funds reported $1.69M of Oncolytics Biotech stock for Q4 2021, down 39% quarter-over-quarter.
  • 12 funds opened new Oncolytics Biotech positions in Q4 2021 and 4 closed out, a net change of +8 holders.
  • The largest Oncolytics Biotech buyer in Q4 2021 was Advisor Resource Council, an estimated $185K added.
  • The largest Oncolytics Biotech seller in Q4 2021 was JP Morgan Chase, an estimated $206K sold.

Based on aggregated 13F filings for Q4 2021.